We are pleased to share a featured interview from the Cellular Therapy and Immunotherapy Conference 2025 (CTI 2025) in Hangzhou, conducted in collaboration with Hematology Frontier.
In this in-depth discussion, Prof. Norbert Claude Gorin of Sorbonne University, France, reflects on the evolving landscape of AML treatment, the role of monoclonal antibodies, and how the integration of novel therapies is reshaping global transplantation strategies. His insights provide valuable context for the future of hematologic innovation and patient care.
This conversation offers meaningful guidance for clinicians, researchers, and professionals dedicated to advancing cellular therapy and transplantation medicine.
CTI 2025 | November 13–16, 2025 | Hangzhou, China
